Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width

Clinical Biochemistry

Volumn 49, Issue 15, 2016, Pages 1167-1172

  Binderup, Helle Glud ^a   Houlind, Kim ^a,b   Madsen, Jonna Skov ^a,b   Brasen, Claus Lohman ^a  

^a KOLDING HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Anti platelet therapy; Aspirin resistance; Biomarker; MicroRNA 92a; PDW

Indexed keywords

ACETYLSALICYLIC ACID; MICRORNA; MICRORNA 92A; UNCLASSIFIED DRUG; MIRN92 MICRORNA, HUMAN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; HUMAN; INTERMITTENT CLAUDICATION; MALE; MONOTHERAPY; PLATELET DISTRIBUTION WIDTH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THERAPY RESISTANCE; THROMBOCYTE FUNCTION ANALYZER; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; CYTOLOGY; DRUG RESISTANCE; MIDDLE AGED; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADULT; ASPIRIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MICRORNAS; MIDDLE AGED; PLATELET AGGREGATION;

EID: 84973531920     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.04.017     Document Type: Article

References (40)

1. [1] WHO | Global atlas on cardiovascular disease prevention and control. WHO n.d. http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/ (accessed September 8, 2014).
2. [2] Dretzke, J., Riley, R.D., Lordkipanidzé, M., Jowett, S., O'Donnell, J., Ensor, J., et al. The prognostic utility of tests of platelet function for the detection of “aspirin resistance” in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. Health Technol. Assess. 19 (2015), 1–366.
3. [3] Badimon, L., Padro, T., Vilahur, G., Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur. Heart J. Acute Cardiovasc. Care 1 (2012), 60–74.
4. [4] Kaplan, Z.S., Jackson, S.P., The Role of Platelets in Atherothrombosis. ASH Educ Program Book 2011, 2011, 51–61.
5. [5] Lordkipanidzé, M., Advances in monitoring of aspirin therapy. Platelets 23 (2012), 526–536.
6. [6] Kovács, E.G., Katona, É., Bereczky, Z., Homoródi, N., Balogh, L., Tóth, E., et al. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb. Res. 133 (2014), 811–816.
7. [7] Gremmel, T., Koppensteiner, R., Panzer, S., Comparison of aggregometry with flow cytometry for the assessment of agonists´-induced platelet reactivity in patients on dual antiplatelet therapy. PLoS One, 10, 2015.
8. [8] Rubak, P., Villadsen, K., Hvas, A.-M., Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry. Thromb. Res. 130 (2012), 420–423.
9. [9] Zampetaki, A., Mayr, M., Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb. Haemost. 108 (2012), 592–598.
10. [10] Laffont, B., Corduan, A., Plé, H., Duchez, A.-C., Cloutier, N., Boilard, E., et al. Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles. Blood 122 (2013), 253–261.
11. [11] Widmer, R.J., Chung, W.-Y., Herrmann, J., Jordan, K.L., Lerman, L.O., Lerman, A., The association between circulating MicroRNA levels and coronary endothelial function. PLoS One, 9, 2014.
12. [12] Jiang, Y., Wang, H., Cao, H., Wang, C., Zhang, L., Wang, H., et al. Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases. Sci. Rep., 4, 2014, 5026.
13. [13] Kim, Y.G., Suh, J.-W., Yoon, C.-H., Oh, I.-Y., Cho, Y.-S., Youn, T.-J., et al. Platelet volume indices are associated with high residual platelet reactivity after antiplatelet therapy in patients undergoing percutaneous coronary intervention. J. Atheroscler. Thromb. 21:5 (2014), 445–453.
14. [14] Multiplate® analyzer. http://www.cobas.com/content/internet/product/cobas/en/home/product/multiplate-analyzer.html (accessed April 17, 2014).
15. [15] Łabuz-Roszak, B., Pierzchała, K., Tyrpień, K., Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking. J. Endocrinol. Investig. 37 (2014), 331–338.
16. [16] Ibrahim, O., Maskon, O., Darinah, N., Raymond, A.A., Rahman, M.M., Aspirin resistance in patients with acute coronary events: risk factors and prevalence as determined by whole blood multiple electrode aggregometry. Pak. J. Med. Sci. 29 (2013), 1319–1322.
17. [17] Pro.medicin n.d. http://pro.medicin.dk/.
18. [18] Scharf, R.E., Drugs that affect platelet function. Semin. Thromb. Hemost. 38 (2012), 865–883.
19. [19] Li, J., Song, M., Jian, Z., Guo, W., Chen, G., Jiang, G., et al. Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence. J. Atheroscler. Thromb. 21 (2014), 239–247.
20. [20] Würtz, M., Grove, E.L., Kristensen, S.D., Hvas, A.-M., The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96 (2010), 368–371.
21. [21] Stepensky, D., Rimon, G., Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects. Expert Opin. Drug Metab. Toxicol. 11 (2014), 41–52.
22. [22] Pulcinelli, F.M., Biasucci, L.M., Riondino, S., Giubilato, S., Leo, A., Renzo, L.D., et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur. Heart J. 30 (2009), 1279–1286.
23. [23] Peace, A., Mccall, M., Tedesco, T., Kenny, D., Conroy, R.M., Foley, D., et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J. Thromb. Haemost. 8 (2010), 2323–2325.
24. [24] Grove, E.L., Hvas, A.m., Mortensen, S.B., Larsen, S.B., Kristensen, S.D., Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J. Thromb. Haemost. 9 (2011), 185–191.
25. [25] Faraday, N., Yanek, L.R., Mathias, R., Herrera-Galeano, J.E., Vaidya, D., Moy, T.F., et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115 (2007), 2490–2496.
26. [26] Williams, F.M., Clinical significance of esterases in man. Clin. Pharmacokinet. 10 (1985), 392–403.
27. [27] Zhou, G., Marathe, G.K., Willard, B., McIntyre, T.M., Intracellular erythrocyte platelet-activating factor Acetylhydrolase I inactivates aspirin in blood. J. Biol. Chem. 286 (2011), 34820–34829.
28. [28] Kalra, K., Franzese, C.J., Gesheff, M.G., Lev, E.I., Pandya, S., Bliden, K.P., et al. Pharmacology of antiplatelet agents. Curr. Atheroscler. Rep. 15 (2013), 1–13.
29. [29] Al-Azzam, S.I., Alzoubi, K.H., Khabour, O., Alowidi, A., Tawalbeh, D., The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Acta Cardiol. 67 (2012), 445–448.
30. [30] Awidi, A., Saleh, A., Dweik, M., Kailani, B., Abu-Fara, M., Nabulsi, R., et al. Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Heart Vessel. 26 (2011), 516–522.
31. [31] Rollini, F., Franchi, F., Cho, J.R., Degroat, C., Bhatti, M., Ferrante, E., et al. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. J. Cardiovasc. Transl. Res. 7 (2014), 53–63.
32. [32] Yarlioglues, M., Ardic, I., Dogdu, O., Akpek, M., Zencir, C., Kasapkara, H.A., et al. The acute effects of passive smoking on mean platelet volume in healthy volunteers. Angiology 63 (2012), 353–357.
33. [33] Chen, X., Zhang, L., Su, T., Li, H., Huang, Q., Wu, D., et al. Kinetics of plasma microRNA-499 expression in acute myocardial infarction. J. Thorac. Dis. 7 (2015), 890–896.
34. [34] Baggish, A.L., Park, J., Min, P.-K., Isaacs, S., Parker, B.A., Thompson, P.D., et al. Rapid upregulation and clearance of distinct circulating microRNAs after prolonged aerobic exercise. J. Appl. Physiol. 116 (2014), 522–531.
35. [35] Willeit, P., Zampetaki, A., Dudek, K., Kaudewitz, D., King, A., Kirkby, N.S., et al. Circulating MicroRNAs as novel biomarkers for platelet activation. Circ. Res. 112 (2013), 595–600.
36. [36] Zhang, L., Zhou, M., Wang, Y., Huang, W., Qin, G., Weintraub, N.L., et al. miR-92a inhibits vascular smooth muscle cell apoptosis: role of the MKK4–JNK pathway. Apoptosis 19 (2014), 975–983.
37. [37] Loyer, X., Potteaux, S., Vion, A.-C., Guérin, C.L., Boulkroun, S., Rautou, P.-E., et al. Inhibition of MicroRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ. Res. 114 (2014), 434–443.
38. [38] Iaconetti, C., Polimeni, A., Sorrentino, S., Sabatino, J., Pironti, G., Esposito, G., et al. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res. Cardiol. 107 (2012), 1–14.
39. [39] Feinberg, M.W., Cao, Z., Wara, A.K., Lebedeva, M.A., SenBanerjee, S., Jain, M.K., Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J. Biol. Chem. 280 (2005), 38247–38258.
40. [40] López-Farré, A.J., Modrego, J., Azcona, L., Guerra, R., Segura, A., Rodríguez, P., et al. Nitric oxide from mononuclear cells may be involved in platelet responsiveness to aspirin. Eur. J. Clin. Investig. 44 (2014), 463–469.